Arax Advisory Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
Arax Advisory Partners's LKFT Position: Q2 2026 in Review
Arax Advisory Partners increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 15% in Q2 2026, buying an estimated $3.83K and bringing the position to 1,009 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3673.
Arax Advisory Partners first reported a position in LKFT in Q3 2022 and has held it in 9 quarters since. The position peaked at $76.4K in Q4 2025. 78 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.
- Arax Advisory Partners held 1,009 shares of Lakefront Biotherapeutics American Depositary Shares worth $30.3K as of Q2 2026.
- Arax Advisory Partners bought 135 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $3.83K.
- Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3673 holding.
- Arax Advisory Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and has held it in 9 quarters since.
- Arax Advisory Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $76.4K in Q4 2025.
- 78 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.